Clinical Trial Update: Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

View source ↗

Summary

A completed real-world study from Sweden examining sequencing of ALK tyrosine kinase inhibitors and therapeutic outcomes in ALK-positive non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ALK tyrosine kinase inhibitors (TKIs) sequencing

Snippet

Sponsor: Pfizer | Conditions: ALK-positive NSCLC | Status: COMPLETED | Results posted: 2022-07-13